Correction to: CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy

An amendment to this paper has been published and can be accessed via the original article.

Source: Cancer Cell International - October 28, 2020 Category: Cancer & Oncology Authors: Seyed Mohammad Miri, Elham Tafsiri, William Chi Shing Cho and Amir Ghaemi Tags: Correction Source Type: research